-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Aethlon Medical Enters Into Materials Transfer Agreement For Santersus AG's NucleoCapture And HemoNucleoCapture Devices
Aethlon Medical Enters Into Materials Transfer Agreement For Santersus AG's NucleoCapture And HemoNucleoCapture Devices
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier Blood Filtration System
SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices.
Under the terms of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture devices, designed to remove Neutrophil Extracellular Traps (NETs), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.
Aethlon will perform initial pre-clinical studies to examine the NucleoCapture and HemoNucleoCapture devices, alone, and in combination with Aethlon's Hemopurifier -- a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids -- to assess their ability to remove important targets in samples from cancer patients, as well as from perfusates from kidneys that have undergone machine perfusion as part of the renal transplantation process.
"We look forward to initiating pre-clinical studies shortly, to expand upon the data that Santersus has generated in sepsis and liver and lung transplantation, and more importantly, to explore potential synergies with our Hemopurifier, initially in oncology and renal transplantation, as well as other potential indications," stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "Our belief is that the NETs removed by the NucleoCapture and HemoNucleoCapture devices, in combination with the clinical mediators removed by our Hemopurifier, could have an additive or synergistic effect in both the cancer and kidney transplant settings. The signing of the MTA represents an important milestone for both companies, as it is the first step toward a potential future collaboration."
"Our collaboration with Aethlon has provided us with research and development partners with expertise and capabilities to help advance our NucleoCapture technology platform forward in important fields, such as oncology and kidney transplantation. We are excited to continue building on the progress we've made in Santersus thus far and on taking the next steps forward in executing on our plans to advance NucleoCapture technology," commented Scott Maguire, Chairman of Santersus. "NETs are being increasingly recognized as an important element in cancer progression and metastasis. We believe extracorporeal removal of NETs using NucleoCapture either alone or in combination with Hemopurifier technology might create a transformational treatment option for patients receiving immune checkpoint inhibitors or CAR T cell therapies."
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier Blood Filtration System
Aethlon Medical将进行临床前研究,以探索其首创的血液净化器血液过滤系统的潜在协同作用
SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices.
圣地亚哥,2024年2月21日 /PRNewswire/ — 专注于开发治疗癌症和危及生命的传染病产品的医学治疗公司艾思龙医疗公司(纳斯达克股票代码:AEMD)今天宣布,它与总部位于苏黎世伦敦的私营治疗医疗器械公司Santersus AG就桑特斯的NucleoCapture和HemonuOCCLEOCLE签订了材料转让协议(MTA)捕获设备。
Under the terms of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture devices, designed to remove Neutrophil Extracellular Traps (NETs), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.
根据MTA的条款,Santersus将向Aethlon提供NucleoCapture和HemonucleoCapture设备,旨在去除中性粒细胞细胞外陷阱(NET),这些陷阱对组织和器官有毒,与癌症、败血症、狼疮等自身免疫性疾病以及器官移植中的缺血再灌注损伤的病理生理学有关。
Aethlon will perform initial pre-clinical studies to examine the NucleoCapture and HemoNucleoCapture devices, alone, and in combination with Aethlon's Hemopurifier -- a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids -- to assess their ability to remove important targets in samples from cancer patients, as well as from perfusates from kidneys that have undergone machine perfusion as part of the renal transplantation process.
Aethlon 将进行初步的临床前研究,单独检查 NucleoCapture 和 HemonucleoCapture 设备,并与 Aethlon 的 Hemopurifier(一种治疗性血液过滤系统,旨在结合和去除血液和其他生物液体中的有害外泌体和危及生命的病毒)结合使用,以评估它们去除癌症患者样本中重要靶标以及从经过治疗的肾脏灌注液中去除重要靶标的能力机器灌注是肾脏移植过程的一部分。
"We look forward to initiating pre-clinical studies shortly, to expand upon the data that Santersus has generated in sepsis and liver and lung transplantation, and more importantly, to explore potential synergies with our Hemopurifier, initially in oncology and renal transplantation, as well as other potential indications," stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "Our belief is that the NETs removed by the NucleoCapture and HemoNucleoCapture devices, in combination with the clinical mediators removed by our Hemopurifier, could have an additive or synergistic effect in both the cancer and kidney transplant settings. The signing of the MTA represents an important milestone for both companies, as it is the first step toward a potential future collaboration."
Aethlon Medical临时首席执行官兼首席财务官詹姆斯·弗雷克斯表示:“我们期待很快启动临床前研究,以扩展Santersus在败血症和肝肺移植中生成的数据,更重要的是,探索与我们的血液净化剂的潜在协同作用,最初是在肿瘤学和肾脏移植以及其他潜在适应症方面。”“我们认为,NucleoCapture和HemonucleoCapture设备去除的神经内分泌物,再加上我们的血液净化器去除的临床介质,可以在癌症和肾脏移植环境中产生增效或协同作用。MTA的签署对两家公司来说都是一个重要的里程碑,因为这是朝着未来潜在合作迈出的第一步。”
"Our collaboration with Aethlon has provided us with research and development partners with expertise and capabilities to help advance our NucleoCapture technology platform forward in important fields, such as oncology and kidney transplantation. We are excited to continue building on the progress we've made in Santersus thus far and on taking the next steps forward in executing on our plans to advance NucleoCapture technology," commented Scott Maguire, Chairman of Santersus. "NETs are being increasingly recognized as an important element in cancer progression and metastasis. We believe extracorporeal removal of NETs using NucleoCapture either alone or in combination with Hemopurifier technology might create a transformational treatment option for patients receiving immune checkpoint inhibitors or CAR T cell therapies."
“我们与Aethlon的合作为我们的研发合作伙伴提供了专业知识和能力,帮助我们在肿瘤学和肾脏移植等重要领域推进我们的NucleoCapture技术平台向前发展。Santersus董事长斯科特·马奎尔评论说,我们很高兴能够继续在Santersus迄今取得的进展基础上再接再厉,继续采取下一步措施来执行我们的推进NucleoCapture技术的计划。“人们越来越认识到,神经内分泌瘤是癌症进展和转移的重要因素。我们认为,单独使用NucleoCapture或与血液净化器技术联合使用体外神经内分泌瘤可能会为接受免疫检查点抑制剂或CAR T细胞疗法的患者创造变革性的治疗选择。”
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧